On 29 October, our Director for Research, Angela Bradshaw, participated in a Steering Committee meeting for the Innovative Health Initiative-funded AD-RIDDLE project in Madrid, Spain. On the margins of the Clinical Trials in Alzheimer’s Disease conference, project and workstream leads met to share updates on progress and plan upcoming activities in the project. Following a warm welcome by project co-Leads Miia Kivipelto and Niranjan Bose, partners and PIs of clinical sites discussed the design and initiation of the AD-RIDDLE study. Involving eight sites in six European countries, the study will test and refine the AD-RIDDLE modular toolbox platform, which comprises an array of tools including digital cognitive assessments and blood-based biomarkers. Running alongside, the AD-RIDDLE implementation study will assess the adoption and use of these innovative tests in the real-world setting. Workstream leads have been organising clinical site visits, to understand the context for implementation and establish an evaluation plan for 2025 onwards. We also heard about advances in designing predictive algorithms for early risk and disease detection, supported by data mapping work to facilitate the provision of analysis-ready datasets - enabled by the European Platform for Neurodegenerative Diseases (EPND). Angela presented an update for the two work packages that AE is leading, which are addressing communications, public involvement, stakeholder engagement, ethics and policy. Learn more about AD-RIDDLE: https://www.ad-riddle.org/
